Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nanosphere Receives FDA Clearance for C. difficile Test

Published: Wednesday, December 12, 2012
Last Updated: Wednesday, December 12, 2012
Bookmark and Share
Comprehensive sample-to-result test detects potentially deadly C. difficile and identifies 027 hypervirulent strain.

Nanosphere, Inc. announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its C.difficile test on the automated sample-to-result Verigene® System.

The C. difficile test expands Nanosphere’s infectious disease test capabilities.  C. difficile infection is a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death.  In less than two hours, the C. difficile test detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain which is associated with increased severity of disease and used for infection control.  Early and accurate diagnosis of C. difficile infections is critical in both the proper treatment of infected patients and subsequent implementation of isolation and containment procedures to prevent further spread of the infection.

“The C. difficile test provides Nanosphere’s customers with a valuable tool to fight these deadly and costly infections,” said Bill Moffitt, Nanosphere’s Chief Executive Officer.  “With four new products cleared by the FDA in the last 12 months, we are pleased to lead the market in providing a comprehensive suite of tests that can improve patient outcomes and reduce healthcare spending” Moffitt stated.

The sample-to-result test automates the steps of bacterial DNA extraction, amplification, hybridization and target detection on the Verigene System.  The ease-of-use and rapid turnaround time of the test allow hospitals of any size to benefit from the speed and accuracy of automated molecular testing.

The C. difficile test complements Nanosphere’s broadening menu of infectious disease tests including:

•    Gram-Positive Blood Culture test (BC-GP) to detect bacteria, including antibiotic resistance markers, that may cause bloodstream infections (510(k) cleared; CE-Mark)
•    Respiratory Virus Plus test (RV+)  to detect multiple respiratory viruses which cause respiratory tract infections (510(k) cleared; CE-Mark)
•    Enteric Pathogens test (EP) to detect and multiple bacteria, viruses and toxin genes which cause gastrointestinal infections (In Clinical Trials )
•    Gram-Negative Blood Culture test (BC-GN) to detect bacteria, including antibiotic resistance markers, that may cause bloodstream infections (In Clinical Trials)

Nanosphere plans to commercialize the enteric pathogens and gram-negative tests in 2013 following receipt of the necessary regulatory approvals.

About C. difficile Infections

C. difficile strikes nearly 500,000 Americans annually and is linked in hospital records to more than 30,000 deaths per year in the United States.  The elderly, immunocompromised, and those recently treated with antibiotics have the greatest risk of acquiring C. difficile infections.  Around 75% of C. difficile infections are acquired in hospitals or nursing homes, with transmission to patients occurring via the hands of healthcare workers or contact with contaminated surfaces2.  Community-acquired cases of C. difficile, however, are on the rise.  The increase in severity of C. difficile infections over the past decade is likely linked to the emergence of the BI/NAP1/027 hypervirulent strain, with C. difficile related deaths increasing 400% over that timespan.  “Hospital billing data collected by the Federal Agency for Healthcare Research and Quality shows that more than 9% of C. diff-related hospitalizations end in death — nearly five times the rate for other hospital stays,” according to a recent USA TODAY investigation1.  Currently, the federal government does not have a system in place to track antibiotic use in healthcare facilities, and there is no Medicare and Medicaid penalty for facilities with high C. difficile rates.  A new C. difficile reporting rule is scheduled to be implemented in 2013 that will now include reporting in nursing homes and rehabilitation centers in addition to hospitals in attempts to combat C. difficile spread.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanosphere Receives FDA Clearance for Respiratory Pathogens Test
Nanosphere, Inc. has announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Verigene® Respiratory Pathogens FlexNucleic Acid Test (RP Flex) on the automated sample-to-result Verigene System.
Wednesday, September 09, 2015
Nanosphere Receives FDA Authorization to Market its Gram-Positive Blood Culture Test
US FDA grants a de novo petition permitting marketing of Gram-Positive BC-GP on the automated Verigene® system.
Friday, June 29, 2012
Nanosphere Announces FDA Clearance of Second Molecular Diagnostics AssayHyper-coagulation Panel
The test is designed to detect disease-associated gene mutations that can contribute to blood coagulation disorders and difficulties metabolizing folate.
Wednesday, October 17, 2007
Nanosphere Awarded U.S. Patent for Biobarcode™ Protein Detection Technology
Biobarcode™ technology is designed for protein detection, for nucleic acid detection and genomics.
Friday, December 16, 2005
Nanosphere Names Dr. Peter G. Schultz to Board of Directors
Dr. Schultz's widely recognized scientific knowledge will enable him to provide strategic guidance to Nanosphere.
Thursday, September 29, 2005
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!